VIDO scientists strengthen mpox preparedness
VIDO scientists have recieved >$1-million in total funding to study mpox (formerly known as monkeypox) from the Canadian Institutes of Health Research “Team Grant: Mpox (monkeypox) and zoonotic threats.”
VIDO led technology a key part of the vaccine protecting koalas from chlamydia
An adjuvant developed by VIDO and partners is a key component in a vaccine to protect koalas from chlamydia. The adjuvant improves the effectiveness of the vaccine by improving the koala immune response.
VIDO and VFI collaborate to strengthen pandemic preparedness
VIDO and the Vaccine Formulation Institute (VFI) sign collaborative research agreement to help drive joint vaccine development and support a rapid and unified response to future pandemics.
VIDO scientists receive leadership awards for excellence in vaccine research
Drs. Darryl Falzarano and Alyson Kelvin have been recognized by the Canadian Institutes of Health Research (CIHR) for their international leadership in vaccine research for infectious diseases.
VIDO partners with four research hubs to strengthen Canada’s infectious disease preparedness
The hubs will help accelerate the research, development, and translation of vaccines therapeutics and diagnostics into commercially viable products and processes. They will also expand skilled talent by supporting training and development.
The avian influenza outbreak: what you need to know
Parts of North America, Europe, Asia, and Africa are currently experiencing outbreaks of H5N1 bird flu. H5N1 is present in all major flyways globally, with millions of affected birds including over 7 million in Canada and 500,000 in Saskatchewan.
Integrating field and laboratory studies to better predict the next emerging zoonotic pathogen
The COVID-19 pandemic, and discovery of SARS-CoV-2–like viruses in Rhinolophus bats, reinforced the need to identify wildlife sources of zoonotic pathogens and to forecast where and when ‘spillover’ to humans is likely.
CIHR supports research targeting high impact infectious diseases
VIDO’s scientists, Drs Neeraj Dhar and Alyson Kelvin, were awarded support from the Canadian Institutes of Health Research Project Grant Fall 2022 Competition to target priority human diseases.
VIDO first non-U.S. organization invited to join high containment network
VIDO has been accepted as the first and only international organization in the Research Alliance for Veterinary Science and Biodefense BSL-3 Network—a partnership of 18 U.S. based large biocontainment facilities focused on veterinary infectious diseases.
Leaders in discovery: five USask researchers honoured with top provincial health awards
Dr. Volker Gerdts, director and CEO of VIDO and professor in the Western College of Veterinary Medicine at the University of Saskatchewan, has been recognized with an Achievement Award by the Saskatchewan Health Research Foundation (SHRF).